Understand the source comparison
Peptides for IBD: Side by Side Comparison
BPC-157 VEGF upregulation, tight junction stabilization, enteric nervous system modulation 47+ animal studies; no human trials Subcutaneous or oral (enteric-coated) Requires -20°C storage; degrades in gastric acid without protection Most robust preclinical evi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, tight junction stabilization, enteric nervous system modulation
- 47+ animal studies; no human trials
- Subcutaneous or oral (enteric-coated)
- Requires -20°C storage; degrades in gastric acid without protection
- Most robust preclinical evidence but zero human safety data. Translation gap is significant
- KPV
- Melanocortin receptor activation, localized NF-kB inhibition
- Limited animal data; mechanistic human cell studies
- Oral or rectal (topical)
- Protease-resistant structure; minimal systemic absorption
- Theoretically ideal for localized colonic inflammation but untested for human tolerability
- Thymosin Alpha-1
- T-regulatory cell enhancement, IL-10 upregulation
- FDA-approved for hepatitis; limited IBD-specific research
- Subcutaneous injection
- Stable at 2–8°C post-reconstitution for 28 days
- Proven human safety profile but mechanism in IBD is extrapolated, not direct
- Thymalin
- Thymic peptide complex; immune modulation
- Primarily ex-USSR research; minimal Western validation
- Subcutaneous or intramuscular
- Refrigeration required; potency verification critical
- Intriguing immunomodulatory profile but evidence base is geographically concentrated